Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Two injections of mRNA-1273, a lipid nanoparticle–encapsulated mRNA-based vaccine produced in collaboration with the NIAID that encodes the SARS-CoV-2 spike protein, conferred protection against Covid-19 illness in 94% of vaccinated patients. Adverse effects of the vaccine were mild, transient local...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-02, Vol.384 (5), p.403-416
Hauptverfasser:	Baden, Lindsey R, El Sahly, Hana M, Essink, Brandon, Kotloff, Karen, Frey, Sharon, Novak, Rick, Diemert, David, Spector, Stephen A, Rouphael, Nadine, Creech, C. Buddy, McGettigan, John, Khetan, Shishir, Segall, Nathan, Solis, Joel, Brosz, Adam, Fierro, Carlos, Schwartz, Howard, Neuzil, Kathleen, Corey, Larry, Gilbert, Peter, Janes, Holly, Follmann, Dean, Marovich, Mary, Mascola, John, Polakowski, Laura, Ledgerwood, Julie, Graham, Barney S, Bennett, Hamilton, Pajon, Rolando, Knightly, Conor, Leav, Brett, Deng, Weiping, Zhou, Honghong, Han, Shu, Ivarsson, Melanie, Miller, Jacqueline, Zaks, Tal
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 Adolescent Adult Adverse events Age Aged Allergies Cardiovascular disease Coronaviridae Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - immunology COVID-19 - prevention & control COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Disease prevention Disease transmission Drug dosages Drug stores Enrollments Female Humans Incidence Infections Infectious diseases Male Middle Aged mRNA Nanoparticles Original Patient Acuity Placebos R&D Research & development SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Single-Blind Method Spike Glycoprotein, Coronavirus Spike protein Treatment Outcome Vaccine efficacy Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Two injections of mRNA-1273, a lipid nanoparticle–encapsulated mRNA-based vaccine produced in collaboration with the NIAID that encodes the SARS-CoV-2 spike protein, conferred protection against Covid-19 illness in 94% of vaccinated patients. Adverse effects of the vaccine were mild, transient local reactions, and the incidence of systemic effects such as fever, headache, and fatigue was low.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2035389